Control of leukemia relapse after allogeneic hematopoietic stem cell transplantation: integrating transplantation with genetically modified T cell therapies

Current Opinion in Hematology
Gianpietro Dotti

Abstract

Leukemia relapse remains a significant cause of failure after allogeneic hematopoietic stem cell transplantation (HSCT). Although it is widely accepted that immunological components of the stem cell graft play a critical role in promoting leukemia eradication (graft versus leukemia effect), it is also evident that their efficacy is frequently inadequate and leukemia relapse still occurs. This article reviews recent insights into T cell-based posttransplant immunotherapy approaches aimed at preventing or controlling leukemia relapse. Donor lymphocyte infusion with T cells genetically modified with safety switches improves the patient's immune reconstitution while offering appropriate control of graft versus host disease. T lymphocytes engineered with artificial tumor-specific receptors such as αβT-cell receptor chains or chimeric antigen receptors are major players in promoting antileukemia effects after allogeneic HSCT. The landscape of adoptive T cell therapies after allogeneic HSCT has seen significant achievements with the introduction of T cell engineering. Gene transfer grants the generation of T cell products characterized by standardizable specificity and functionality. This aspect is critical for scalable and reproducib...Continue Reading

References

May 10, 1979·The New England Journal of Medicine·P L WeidenR Storb
Sep 1, 1988·The Journal of Clinical Investigation·P J VoogtJ H Falkenburg
May 29, 1998·The Journal of Clinical Investigation·P YotndaP Langlade-Demoyen
Mar 12, 1999·Annual Review of Medicine·D L Porter, J H Antin
Mar 20, 2001·Hematology/oncology Clinics of North America·T G Martin, J L Gajewski
Apr 20, 2002·Cancer Control : Journal of the Moffitt Cancer Center·Leo Luznik, Ephraim J Fuchs
Feb 22, 2005·Nature Biotechnology·Yi LiJonathan M Boulter
Feb 25, 2005·Blood·Karin C StraathofCliona M Rooney
Jun 28, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Martin A PulèMalcolm K Brenner
Dec 20, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Katayoun RezvaniA John Barrett
Sep 2, 2006·Science·Richard A MorganSteven A Rosenberg
Jul 21, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Siok-Keen TeyMalcolm K Brenner
Oct 30, 2007·Blood Cells, Molecules & Diseases·Loredana RuggeriAndrea Velardi
May 28, 2008·Best Practice & Research. Clinical Haematology·Noelle V Frey, David L Porter
Sep 16, 2008·Best Practice & Research. Clinical Haematology·Jacob M Rowe
Dec 16, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Maria R ParkhurstSteven A Rosenberg
Feb 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul F RobbinsSteven A Rosenberg
May 5, 2011·The Journal of Clinical Investigation·Barbara SavoldoGianpietro Dotti
Nov 4, 2011·The New England Journal of Medicine·Antonio Di StasiMalcolm K Brenner
Apr 13, 2012·The New England Journal of Medicine·Martin SchrappeMartin Zimmermann
Aug 31, 2012·The New England Journal of Medicine·Jeffrey M VenstromKatharine C Hsu

❮ Previous
Next ❯

Citations

May 25, 2016·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Luca CastagnaLucio Morabito
Oct 19, 2017·The Journal of Experimental Medicine·Abdulraouf RamadanSophie Paczesny

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.